- Nov 30 | Bio-IT World | Illumina powers the Canadian COVID-19 Genomics Network, organ-on-a-chip explores infectious disease, and cell analysis acquisitions. Plus new products from PerkinElmer, Bio-Rad, Roswell Biotechnologies, Genialis, and more. More
- Nov 23 | Bio-IT World | Genomics and artificial intelligence (AI) are key to this quest and at-scale advancement of personalized medicine. Both, however, require liquid data and modern data infrastructure that re-imagines the role of data and how it is used. More
- Nov 22 | Bio-IT World | Evidence has been mounting for decades that what men eat can lower or raise their risk of prostate cancer—including aggressive forms of the disease that can be lethal. But that’s only part of the story. More
- Nov 19 | Bio-IT World | Worldwide spending on pharmaceutical R&D will reach $230 billion by 2026. So with investment dollars flowing in and R&D continuing an upward trajectory all should be well, right? Well… not exactly. Like many industries, pharmaceutical companies are facing a data problem—a dark data problem. More
- Nov 17 | Bio-IT World | As a “digital native,” Recursion is working to reshape the drug discovery industry—quite literally. Gone is the vision of a traditional discovery funnel, wide at the top and slowly narrowing. Instead, Recursion proposes a drug discovery machine powering a T-shaped funnel where many options are considered, but failure is fast and the candidates that advance have a potentially higher likelihood of being a successful treatment. Easier said than done. More
- Nov 16 | Bio-IT World | Trials for Alzheimer’s disease (AD) drugs have repeatedly failed with billions of dollars invested. But a new, multidisciplinary drug repurposing model, described in a recent article in Nature Aging, combines drug repurposing with precision medicine, network-based drug targeting, induced pluripotent stem cell (iPSC) technology, and real-world data analysis. More
- Nov 24 | More
Global Multi-Omics Market Research Report – Collective Technologies that are Defining a New Era for Integrative MedicineNov 24 | The next phase of market growth is likely to be driven by rising demand for personalized medicine, technological advancements, favourable funding environment, growing incidence of cancer & genetic disorders. More
Pistoia Alliance predicts a focus on the fight against antimicrobial resistance and a surge in quantum computing research for 2022Nov 24 | Innovation experts Linda Kasim, Imran Haq and Anca Ciobanu share predictions for innovation in life sciences for the year ahead More
- Nov 24 | More
- Nov 24 | More
InsightRX’s Precision Medicine Technology to Help Improve Care for Patients Receiving Stem Cell TransplantsNov 24 | InsightRX’s Precision Medicine Technology to Help Improve Care for Patients Receiving Stem Cell Transplants More
Stilla Technologies secures financing of more than €31 million adding Casdin Capital and the European Investment Bank to existing investorsNov 24 | Stilla Technologies, the multiplex digital PCR company, has secured more than €31 million in new financing, adding Casdin Capital and the European Investment Bank (EIB) in addition to new funding from existing investors Illumina Ventures, Kurma Partners, TusPark Capital Management (Luxembourg) S.à r.l., LBO France, BNP Paribas Développement, and Eurazeo. More
- Nov 24 | Applied BioMath, the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), was listed as one of the top ten biosimulation solution companies for 2021 by Pharma Tech Outlook. More
- Nov 19 | In a study that builds on earlier research that identified macrophages as essential to regeneration in the axolotl, a highly regenerative salamander, James Godwin, Ph.D., a scientist at the MDI Biological Laboratory in Bar Harbor, Maine, has identified the source of these critical white blood cells as the liver. By giving scientists a place to look for pro-regenerative macrophages in humans, the discovery brings science a step closer to being able to regenerate tissues and organs lost to injury or disease in humans. More
- Nov 19 | More
Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and
data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!
Digital Therapeutics: Taking digital health to a new level
Benchling is the most widely-adopted life sciences R&D cloud. Accelerate, measure, and forecast R&D – from discovery through bioprocessing – all in one place. It’s a fully unified platform that centralizes and standardizes all R&D data, so you can spend less time fighting with legacy software, and more time reaching breakthrough discoveries.
Read more here!